Agios Pharmaceuticals has retired 14.2% of its shares since 2020, from 69,601,332 to 59,701,882.
At $31.32 a share, a market value of $1.9B. FCF yield -19.5%, P/E n/m, trailing twelve months to June 2026.
| Fiscal year | Date | Shares outstanding | Filing | |
|---|---|---|---|---|
| 2017 | 2018-02-09 | 57,326,741 | 10-K | |
| 2018 | 2019-02-08 | 58,395,419 | 10-K | |
| 2019 | 2020-02-13 | 68,513,573 | 10-K | |
| 2020 | 2021-02-18 | 69,601,332 | 10-K | |
| 2021 | 2022-02-18 | 54,637,501 | 10-K | |
| 2022 | 2023-02-17 | 55,285,223 | 10-K | |
| 2023 | 2024-02-09 | 56,194,847 | 10-K | |
| 2024 | 2025-02-07 | 57,296,167 | 10-K | |
| 2025 | 2026-02-06 | 58,592,172 | 10-K |
Source: all 10-K filings of Agios Pharmaceuticals on EDGAR. Download this series as CSV. Licence CC BY 4.0, credit Buyback Radar.
Loading the chart from TradingView…
All-time chart by TradingView. Open it on TradingView →
Not on a net basis. Agios Pharmaceuticals has 2.4% more shares outstanding than twelve months ago. Whatever it bought back did not cover the new shares it issued. Over five years the share count is up 9.9%.
Net of every new share it issued, Agios Pharmaceuticals has 9.9 million fewer shares than at its 2020 peak. That is 14.2% of the company.
59,701,882 shares, as of July 24, 2026, from the cover page of its latest 10-Q. At the 2020 peak it had 69,601,332.
Each share is a bigger slice of the company. Someone who held Agios Pharmaceuticals stock in 2020 owns 1.2 times as much of the business today without buying another share. Whether that was a good use of cash depends on the price paid.
Agios Pharmaceuticals ranks No. 431 of 467 companies on Buyback Radar by share of the company retired since its peak. Close to it on the list: Generac (14.6%), Woodward (14.3%), Texas Capital Bancshares (14.1%), Brown-Forman (14.1%).
Every answer is computed from Agios Pharmaceuticals' own SEC filings and rebuilt every Monday. Latest count: 10-Q on EDGAR.
The numbers say what happened. The story says whether it can continue. We cover companies like Agios Pharmaceuticals in depth on Cannibal Stocks.
Read Cannibal Stocks